MedPath

JNJ-40411813

Generic Name
JNJ-40411813
Drug Type
Small Molecule
Chemical Formula
C20H25ClN2O
CAS Number
1127498-03-6
Unique Ingredient Identifier
612BYT76F3
Background

JNJ-40411813 has been used in trials studying the treatment and basic science of Confusion, Schizophrenia, Perceptual Disorders, and Major Depressive Disorder.

Clinical Trials
Related News

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Phase 2
Completed
Conditions
Focal Onset Seizures
Interventions
Drug: Placebo
First Posted Date
2021-04-08
Last Posted Date
2025-01-13
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
110
Registration Number
NCT04836559
Locations
🇵🇱

NEURO MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna, Katowice, Poland

🇵🇱

Centrum Leczenia Padaczki i Migreny NZOZ, Krakow, Poland

🇵🇱

Centrum Opieki Zdrowotnej Orkan Med Stec Michalska sj, Ksawerow, Poland

and more 66 locations

A Study of JNJ-40411813 in Healthy Japanese Male Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Matching Placebo
First Posted Date
2020-12-21
Last Posted Date
2025-04-28
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
39
Registration Number
NCT04677530
Locations
🇯🇵

Souseikai Fukuoka Mirai Hospital, Fukuoka-shi, Japan

A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2013-09-26
Last Posted Date
2013-09-26
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
18
Registration Number
NCT01951053

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2013-08-30
Last Posted Date
2013-08-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
36
Registration Number
NCT01932333

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2012-04-23
Last Posted Date
2015-06-16
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
121
Registration Number
NCT01582815

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2011-05-23
Last Posted Date
2013-07-09
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
13
Registration Number
NCT01358006

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: Antipsychotic medication
Drug: Placebo
First Posted Date
2011-03-25
Last Posted Date
2014-05-30
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
100
Registration Number
NCT01323205

Ketamine Challenge Study With JNJ-40411813

Phase 1
Completed
Conditions
Perceptual Disorders
Confusion
Schizophrenia
Interventions
Drug: Placebo
Drug: normal saline
First Posted Date
2010-04-12
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
40
Registration Number
NCT01101659
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy